Orlistat - Roche
Alternative Names: Orlipastat; R 212; RO 180647; Tetrahydrolipstatin; XenicalLatest Information Update: 30 Aug 2024
Price :
$50 *
At a glance
- Originator Roche
- Class Anorectics; Lactones; Obesity therapies; Small molecules
- Mechanism of Action Lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Obesity
Most Recent Events
- 30 Aug 2024 3869649- Obesity therapies to be added as DC; NIO sponsored abstract of a well launched drug and there is no particular trial data, hence not captured
- 03 Jan 2018 Orlistat market-licensed to H2-Pharma for Obesity in USA
- 03 Jan 2018 Orslistat licensed to Cheplapharm Arzneimittel for Obesity in USA